Abstract
A study on page 938 reports the identification of an ovarian and uterine tumor-associated ligand, RCAS1, which inhibits growth of activated T lymphocytes.
This is a preview of subscription content, log in via an institution to check access.
References
Seliger, B., Maeurer, M.J. & Ferrone, S. TAP off—tumors on. Immunol. Today 18, 292–299 (1997).
Pitti, R.M, et al. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 396, 699– 703 (1998).
Walker, P.R., Saas, P. & Dietrich, P.-Y. Tumor expression of Fas ligand (CD95L) and the consequences. Curr. Opin. Immunol. 10, 564– 572 (1998).
Gimmi, C.D. et al. Breast cancer-associated antigen, DF3/MUC1, induces apoptosis of activated human T cells. Nature Med. 2, 1367–1370 (1996).
Levy, L.S. & Bost, K.L. Mechanisms that contribute to the development of lymphoid malignancies: roles for genetic alterations and cytokine production. Crit. Rev. Immunol. 16, 31– 57 (1996).
Nakashima M., Sonoda K. & Watanabe K. Inhibition of cell growth and induction of apoptotic cell death by the human tumor-associated antigen, RCAS1. Nature Med. 5, 938–942 ( 1999).
Greenfield, E.A., Nguyen, K.A. & Kuchroo, V.K. CD28/B7 costimulation: a review. Crit. Rev. Immunol. 18, 389–418 (1998).
Van den Eynde, B.J. & van der Bruggen, P. T cell defined tumor antigens. Curr. Opin. Immunol. 9, 684–693 (1997).
Seino, K.-I., Kayagaki, N., Okumura, K. & Yagita, H. Antitumor effect of locally produced CD95 ligand. Nature Med. 3, 165–170 (1997).
Disis, M.L. & Cheever, M.A. HER-2/neu oncogenic protein: issues in vaccine development. Crit. Rev. Immunol. 18, 37–45 (1998).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Villunger, A., Strasser, A. The great escape: Is immune evasion required for tumor progression?. Nat Med 5, 874–875 (1999). https://doi.org/10.1038/11311
Issue Date:
DOI: https://doi.org/10.1038/11311
- Springer Nature America, Inc.
This article is cited by
-
Alterations of HLA class I expression in human melanoma xenografts in immunodeficient mice occur frequently and are associated with higher tumorigenicity
Cancer Immunology, Immunotherapy (2010)
-
Dendritic cells engineered to express CD40L continuously produce IL12 and resist negative signals from Tr1/Th3 dominated tumors
Cancer Immunology, Immunotherapy (2006)
-
Death receptors in chemotherapy and cancer
Oncogene (2004)
-
Induction of antitumor immunity by transduction of CD40 ligand gene and interferon-γ gene into lung cancer
Cancer Gene Therapy (2001)